We are pleased to announce that Totus Medicines, a frontrunner in clinical-stage biotechnological research, will be presenting four substantive posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The focus will be on our primary drug candidate, TOS-358, an innovative covalent PI3Kα inhibitor.

Preliminary research on TOS-358 indicates its potential, achieving nearly 100% inhibition of PI3Kα activity. As many of you are aware, PI3Kα is a central enzyme in the PI3K/AKT/mTOR signaling pathway, frequently deregulated in various cancer manifestations.

The forthcoming AACR presentation will elaborate on:

  1. Efficacy of TOS-358: The drug has demonstrated the capability to achieve >95% inhibition of PI3Kα, essential for anti-tumor efficacy.
  2. Pathway Feedback Mechanisms: TOS-358 has shown a distinctive property of inhibiting standard feedback mechanisms that typically re-activate PI3Kα in most cellular structures.
  3. Target Specificity: Due to its precise targeting of PI3Kα, TOS-358 minimizes the risk of significant metabolic disruptions.

Mr. Neil Dhawan, CEO and co-founder of Totus Medicines, has remarked, "The data we will present at the AACR is of paramount significance, indicating the preclinical efficacy, safety, and unique positioning of TOS-358 in the realm of PI3Kα inhibitors."

We encourage interested stakeholders to review our poster presentations, the details of which are as follows:

  1. An evaluation of the safety and tolerability of TOS-358 in adult patients with specific solid tumors.
  2. Introduction and validation of a pharmacodynamic assay for TOS-358, marking its position as the pioneering covalent inhibitor of PI3Kα under clinical development.
  3. A detailed study on the necessity of inhibiting wild-type PI3Kα signaling for lasting efficacy in PI3Kα mutant cancer cells.
  4. An assessment of TOS-358's efficacy, ensuring it does not induce significant hyperglycemia at efficacious doses across diverse animal models.

At Totus Medicines, our mission remains steadfast: to develop pioneering therapies capable of enhancing the quality of life for cancer patients. We anticipate our upcoming presentation at AACR to be a significant step toward our collaboration with the wider cancer research community.

View Press Release